Posts

Boehringer Ingelheim partners with Immunai on $15M AI‑driven T‑cell collaboration

on
German drugmaker Boehringer Ingelheim has signed a multi‑project collaboration with AI‑driven biotech Immunai, initially worth up to $15 million through 2027 The deal focuses on decoding T‑cell dysfunction common to both cancer and autoimmune diseases Immunai will use its single‑cell AI platform (AMICA‑OS) to analyze thousands of patient samples and then validate promising targets in its wet lab, with the goal of feeding new programs into Boehringer’s pipeline Sources: With $15M, BI becomes latest to buy into Immunai's AI platform Immunai imports $215m in series B funding - Global Venturing Immunai and AstraZeneca Expand AI-Driven Biomarker ... Immunai signs up to $15 million research pact with Boehringer ... Immunai Raises $60M to Reprogram Immunity Andrii Buvailo, Ph.D.'s Post Immunai - CTech AstraZeneca in AI collaboration with Immunai to inform cancer drug trials Meta Pharmaceuticals lands $15M to make autoimmune drugs with ... Immunai announces a ...

FDA drops blood pressure device enforcement against Whoop

on

Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War

on

Ionis scores transformational FDA label expansion for Tryngolza

on

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

on

Remix to take Nasdaq listing from Passage Bio in reverse merger for mRNA degrader platform

on

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering – June 24, 2026

on

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

on

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

on

No recent news about former employee suing BioNTech for cutting corners in pancreatic cancer trials found in current search results. The available information does not mention any such lawsuit or allegations related to BioNTech or pancreatic cancer trials involving a former employee. Thus, there is no recent news on this specific claim at this time.

on

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

on

Novartis pays Antares $105M to illuminate undruggable cancer targets

on

RQ Bio raises $115M to advance long‑acting flu prevention antibody into clinic

on